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The purpose of this study is to evaluate the dose–volume metrics under different heterogeneity corrections
and the factors associated with local recurrence (LR) after stereotactic body radiation therapy (SBRT) for
non-small-cell lung cancer (NSCLC). Eighty-three patients who underwent SBRT for pathologically proven
stage I NSCLC were reviewed retrospectively. The prescribed dose was 48 Gy in four fractions at the iso-
center (IC) under heterogeneity correction with the Batho power law (BPL). The clinical plans were recalcu-
lated with Eclipse (Varian) for the same monitor units under the BPL and anisotropic analytical algorithm
(AAA) and with no heterogeneity correction (NC). The dose at the IC, dose that covers 95% of the volume
(D95), minimum dose (Min), and mean dose (Mean) of the planning target volume (PTV) were compared
under each algorithm and between patients with local lesion control (LC) and LR. The IC doses under NC
were significantly lower than those under the BPL and AAA. Under the BPL, the mean PTV D95, Min and
Mean were 8.0, 9.4 and 7.4% higher than those under the AAA, and 9.6, 9.2 and 4.6% higher than those
under NC, respectively. Under the AAA, all dose–volumetric parameters were significantly lower in T1a
patients than in those with T1b and T2a. With a median follow-up of 35.9 months, LR occurred in 18
patients. Between the LC and LR groups, no significant differences were observed for any of the metrics.
Even after stratification according to T-stage, no significant difference was observed between LC and LR.
Keywords: lung cancer; stereotactic body radiation therapy; dose–volume metrics; heterogeneity correction;
local control
INTRODUCTION
Stereotactic body radiotherapy (SBRT) is an innovative
technique using multiple narrow beams with high precision,
which enables tumor irradiation with a high, limited, focal
dose [1, 2]. SBRT is an effective treatment option for
patients with stage I non-small-cell lung cancer (NSCLC)
who are inoperable or who refuse surgery. Many single-
institution reports have indicated that SBRT for stage I
NSCLC can achieve a high local control (LC) rate with
minimal toxicity [3–6]. The reported 3-year LC rate ranges
from 80 to 95% [3–7]. The recently disclosed results of
prospective multicenter phase II trials [8–10] have also
shown the efficacy of lung SBRT.
Despite these high LC rates, some patients experience
local progression after SBRT. Several authors have indicated
that the delivered dose is one of the factors affecting the LC
rate after SBRT [7, 11] as well as the tumor diameter [6, 12].
Onishi et al. [7] showed a correlation between biologically
effective dose (BED) at the isocenter (IC) and LC. Wulf
et al. [11] concluded that the peripheral dose to the planning
target volume (PTV) was a significant factor in LC.
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Since we started SBRT for NSCLC in 1998, most
patients have been treated with a uniform dose-fractionation
schedule of 48 Gy in four fractions, equivalent to a
BED10Gy of 105.6 Gy at the IC. However, the dose cover-
age at the PTV varies among patients. Additionally, all the
SBRT plans were calculated with pencil-beam convolution
with heterogeneity correction using the Batho power law
(BPL), which uses the tissue–air ratio as a collection factor
and only partly accounts for the scattering around the in-
homogeneity regions [13].Therefore, the calculated dose
distributions under the BPL are inaccurate, especially at the
periphery of the PTV.
To calculate dose distribution more accurately, a newer
method of heterogeneity correction has been developed.
The anisotropic analytical algorithm (AAA), which is avail-
able in Eclipse (Varian Medical Systems, Palo Alto, CA,
USA), is a more accurate algorithm for heterogeneity cor-
rection. Several reports have shown the superiority of the
AAA over the BPL in the inhomogeneity area [14–16].
However, most of the published SBRT results were based
on earlier dose-calculation algorithms. In the Radiation
Therapy Oncology Group (RTOG) 0236 phase II trial, the
prescribed dose was 60 Gy in three fractions to cover 95%
of the volume of the PTV (PTV D95), calculated under no
heterogeneity correction (NC). The Japan Clinical
Oncology Group (JCOG) 0403 phase II trial used a simple
one-dimensional equivalent path correction as the inhomo-
geneity correction algorithm for the IC prescription, and
the ongoing phase I dose-escalation study of SBRT for
T2N0M0 NSCLC prescribed to the PTV D95 using super-
position/convolution algorithms. When interpreting these
outcomes, we need to consider the effect of the heterogen-
eity correction method and how great the difference is.
In this study, we evaluated the dose–volume metrics in
clinical SBRT plans under the BPL and AAA, and NC,
and then identified factors associated with LR after SBRT
for Stage I NSCLC.
MATERIALS AND METHODS
Patients
From September 2003 to March 2009, 89 patients treated
with SBRT for histologically confirmed stage I NSCLC in
our institution were reviewed retrospectively. Of these, six
patients without LR who were observed for less than 12
months after the completion of SBRT were excluded.
Consequently, this study evaluated 83 patients (61 males,
22 females; median age 77 (range 63–88) years). The hist-
ology was adenocarcinoma in 39 patients, squamous cell
carcinoma in 33, large-cell carcinoma in one and
non-small-cell carcinoma (not specified) in 10. The clinical
T-stage was T1a in 30 patients, T1b in 25 and T2a in 28
according to the seventh edition of the TNM Classification
of Malignant Tumors. The mean tumor diameter was 25.2
(range 10–43) mm. The patient characteristics are summar-
ized in Table 1.
SBRT procedure
The details of the setup and treatment planning at our insti-
tution have been reported previously [17, 18]. The treatment
plans were made using Eclipse (Varian Medical Systems)
and calculated under heterogeneity correction using the
BPL. The prescribed dose was 48 Gy in four fractions at
the IC. The patients were immobilized with a Stereotactic
Body Frame (Elekta, Stockholm, Sweden) before April
2008; thereafter, with the BodyFix system (Medical
Intelligence, Schwabmunchen, Germany). The internal
target volume (ITV) was contoured using computed tomog-
raphy (CT) with a slow-scan technique with a rotation time
of 4 s, considering the tumor motion assessed using X-ray
fluoroscopy. Since October 2006, four-dimensional (4D)
CT was available, thereafter 4DCT images were also
acquired to determine ITV. The PTV was defined as the
ITV with an additional 5-mm margin for setup uncertainty.
The treatment beam was collimated to the PTV with a
5-mm margin using a multileaf collimator to ensure the per-
ipheral dose of the PTV. In all cases, irradiation was
applied with five to eight noncoplanar static beams with a
6-MV X-ray using a Clinac 2300 C/D (Varian Medical
Systems) for patients treated before April 2008 and a
Novalis system (BrainLAB, Feldkirchen, Germany) there-
after. All patients were set up with skeletal anatomy using
megavoltage portal imaging or the Novalis kilovoltage
imaging system.
Follow-up and local assessment
The regular follow-up visits and chest CT were performed
as reported [6]. LR was diagnosed on the basis of enlarge-
ment of the local tumor on CT that continued for at least 6
months or histologic confirmation. 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) was recom-
mended when LR was suspected, but this was not manda-
tory. For patients who could tolerate salvage surgery, LR
was confirmed at surgical resection.
Dose–volume evaluation
The SBRT plans that were used clinically were recalculated
using Eclipse ver. 8.6 using the monitor units irradiated
clinically under the following three different conditions of
heterogeneity correction: (1) pencil beam convolution with
heterogeneity correction using BPL version 8.6.15; (2)
AAA with heterogeneity correction version 8.6.15; and (3)
pencil-beam convolution with NC version 8.6.15. First, the
dose–volume metrics of the PTV under each algorithm
were compared. The evaluated parameters were the dose at
the IC (IC dose), PTV D95, the minimum dose of the PTV
(PTV Min) and the mean dose of the PTV (PTV Mean).
Then, these dose–volumetric parameters were compared
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between LC and LR groups under each algorithm. This
comparison was performed for whole patients and for strati-
fied groups according to the T-stage.
Statistical analysis
All statistical analysis was performed using IBM SPSS
Statistics version 19 (IBM, Armonk, NY, USA). Tukey’s
honestly significant difference test was used to assess the
differences among the three algorithms. Student’s t-test and
Pearson’s chi-square test were used to assess difference
between the LC and LR groups. When the P-value was
<0.05, the difference was deemed statistically significant.
RESULTS
Comparison of the dose–volume metrics under
different algorithms
The averaged dose–volume histograms (DVHs) for the
PTV under the three algorithms are plotted in Fig. 1, and
the mean values and ranges of the dose–volume metrics
under each algorithm are shown in Table 2.
The mean IC dose under BPL, AAA and NC was 48.2,
48.4 and 44.9 Gy, respectively. Under NC, the IC dose was
significantly lower than under the other two algorithms
(P < 0.001), whereas there was no significant difference in
the IC dose between BPL and AAA (P = 0.464). The PTV
D95 under BPL was significantly higher than that under
AAA and NC (P < 0.001), whereas the PTV D95 under
AAA was higher than that under NC (P = 0.034), although
the difference was small (mean value 42.3 vs. 41.7 Gy, re-
spectively). For PTV Min, the value under BPL was sig-
nificantly higher than under AAA and NC (P < 0.001),
whereas there was no significant difference between AAA
and NC. The PTV Mean under BPL was the highest of the
three algorithms, and the value under AAA was higher than
that under NC (P < 0.001). Under BPL, the mean PTV
D95, PTV Min and PTV Mean were 8.0, 9.4 and 7.4%
higher than under AAA, and 9.6, 9.2 and 4.6% higher than
under NC, respectively.
Table 1. Patient characteristics (n = 83)
Characteristics All LC LR P-values
n = 83 n = 65 n = 18 LC vs. LR
Age (years) 0.989
Median 77 77 76.5
[Range] [63–88] [63–87] [63–88]
Gender 0.642
Male 61 47 14
Female 22 18 4
Histology 0.532
Adenocarcinoma 39 33 6
Squamous cell carcinoma 33 24 9
Large cell carcinoma 1 1 0
NSCLC (not specified) 10 7 3
T-stage 0.535
T1a (≤20 mm) 30 25 5
T1b (>20 to ≤30 mm) 29 23 6
T2a (>30 to ≤50 mm) 24 17 7
Tumor diameter (mm) 0.336
Mean 25.2 24.7 26.7
[Range] [10–43] [10–43] [11–37]
PTV volume (cm3) 0.780
Mean 36.1 35.8 37.1
[Range] [9.9–86.6] [9.9–86.6] [12.6–60.4]
NSCLC, non-small-cell lung cancer; LC, patients with local lesion control; LR, patients who developed local recurrence.
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Under AAA, the dose–volume metrics were related to
the tumor diameter. Dividing the patients according to
T-stage, the IC dose, PTV D95, PTV Min and PTV Mean
were significantly lower in the T1a patients than those
values in patients with larger tumors, 47.8 vs. 48.7 Gy
(P = 0.002), 41.2 vs. 43.0 Gy (P < 0.001), 38.1 Gy vs. 39.7
(P = 0.001) and 44.4 Gy vs. 46.3 Gy (P < 0.001), respect-
ively. No significant difference was observed in those para-
meters between T1b and T2a. Accordingly, the difference
in the dose–volume metrics between BPL and AAA was
larger in smaller tumors; the mean PTV D95, PTV Min
and PTV Mean calculated under BPL were 11.4, 13.3 and
12.8% higher than the respective values under AAA in the
T1a patients.
Status of local control
With a median follow-up of 35.9 (range 13.6–81.9)
months, LR was observed in 18 patients (21.7%). The
median time to LR was 17.5 (range 7.4–55.0) months. LR
was confirmed at salvage surgery in six patients, diagnosed
radiologically with CT and FDG-PET in six patients, and
diagnosed with CT only in six patients. The patient charac-
teristics in the LR and LC groups are shown in Table 1.
Tumor diameter and PTV volume in LR tended to be
greater than in LC, but no significant difference was
observed in the clinical factors between the LC and LR
groups.
Comparison of the dose–volume metrics between
the LC and LR groups
The averaged DVHs for the PTV in the LC and LR groups
under the three algorithms are plotted in Fig. 2, and the
mean values and ranges of the dose–volume metrics are
shown in Table 3. No significant difference between the
LC and LR groups was observed in any of the metrics.
Consequently, we stratified the patients into T1a, T1b and
T2a and re-evaluated the dose–volume parameters between
the LC and LR groups; however, none of the dose–volume
metrics differed significantly.
DISCUSSION
The dose–volume metrics differed significantly among the
algorithms we used for heterogeneity correction. Task
Group No. 65 (TG-65) of the Radiation Therapy
Committee of the American Association of Physicists in
Medicine [13] classified the algorithms for heterogeneity
correction into Categories 1 to 4 according to the level of
anatomy sampled for the scatter calculation and the inclu-
sion or exclusion of electron transport. BPL is classified as
a Category 1 algorithm (no electron transport and one-
dimensional density sampling) and AAA as Category 4
(electron transport and three-dimensional density sampling).
In a phantom study, Bragg and Conway [14] reported that
the difference between the dose calculated using AAA and
the dose measured experimentally was within 2.5% or 2
mm in the presence of heterogeneity. Ronde and Hoffmann
[15] showed the superiority of AAA over BPL and
Fig. 1. The averaged dose–volume histogram for the PTV under
BPL, AAA and NC BPL, under heterogeneity correction with the
Batho power law; AAA, under heterogeneity correction using
the anisotropic analytical algorithm; NC, no heterogeneity
correction.
Table 2. Mean values [range] of the dose–volume metrics under each algorithm
Metrics BPL AAA NC P-values
BPL-AAA BPL-NC AAA-NC
IC dose (Gy) 48.2 [47.9–48.5] 48.4 [43.1–49.6] 44.9 [41.7–48.2] 0.464 <0.001 <0.001
PTV D95 (Gy) 45.7 [40.9–46.8] 42.3 [36.1–46.3] 41.7 [37.9–45.4] <0.001 <0.001 0.034
PTV Min (Gy) 42.9 [36.2–45.3] 39.2 [30.9–43.4] 39.3 [33.5–43.7] <0.001 <0.001 0.726
PTV Mean (Gy) 47.7 [46.9–48.4] 45.6 [38.8–49.1] 44.4 [41.1–47.1] <0.001 <0.001 <0.001
IC dose, the dose at the isocenter; PTV D95, the dose that covers 95% of the PTV; PTV Min, the minimum dose of the PTV; PTV
Mean, the mean dose of the PTV. The other abbreviations are as in Fig. 1.
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demonstrated that the dose deviation in lung lesions under
AAA was <3% for most plans. The TG-65 [13] recom-
mends that a Category 4 algorithm be considered in order
to ascertain the dosage at tumor/lung interfaces in radiation
planning for the lung and that simplistic one-dimensional
equivalent path corrections are reasonable only for point
dose estimations for lung tumors.
To our knowledge, our report is the largest study to
compare the dose–volume metrics under BPL, AAA and
NC directly using clinical plans. Our results regarding the
difference in dose–volume metrics with heterogeneity cor-
rection status concur with reports based on fewer cases.
Xiao et al. [19] compared 20 plans in the RTOG protocol
and the same plans calculated using superposition/convolu-
tion algorithms. The volume of the PTV receiving the pre-
scribed dose decreased by >10%, and the PTV D95
decreased by 4.7 Gy with heterogeneity correction. Ding
et al. [16] recalculated 10 lung SBRT treatment plans under
AAA and the modified Batho, which was originally calcu-
lated under NC. The calculated dose distributions near the
interface under AAA agreed with those from a Monte
Carlo simulation and measured values. The difference
between AAA and NC in the PTV D95 was within 10%,
whereas there were differences of up to 45% in the PTV
D95 between NC and the modified Batho. Schuring and
Hurkmans [20] evaluated 26 plans optimized under NC
and the equivalent path length (EPL) by recalculating them
using superposition/convolution algorithms. They con-
cluded that the dose to the PTV margin was overestimated
under the EPL, and the overestimation of the dose increased
with decreasing PTV size. As we found no significant dif-
ference in the IC dose between the BPL and AAA, the
BPL is acceptable for calculating the IC dose for a tumor
of a certain size. However, the BPL cannot accurately
predict the peripheral dose of the PTV (Min or D95). In
our study, the PTV D95 and PTV Min calculated under the
BPL were overestimated compared with the AAA by 8.0%
and 9.4% in all patients and by 11.4% and 13.3% in the
T1a patients.
Although we evaluated IC dose and peripheral dose of
the PTV, we could not find any correlation between either
of the dose–volume metrics and the LC rate, even when
reevaluated under AAA. The doses at the IC and PTV
margin are thought to affect the LC rate after SBRT [7, 11].
Onishi et al. [7] retrospectively reviewed 257 patients with
stage I NSCLC treated with SBRT using various dose-
fractionation schedules and evaluated the LC rate according
to BED at IC. The LR rate was significantly lower for
patients with a BED10Gy ≥100 Gy compared with those
with a BED10Gy <100 Gy (8.4 vs. 42.9%). Wulf et al. [11]
evaluated the relationship between LC status and different
Fig. 2. Averaged dose–volume histogram under each
heterogeneity correction status in LC and LR under BPL (a),
AAA (b) and NC (c). LC, patients with local lesion control; LR,
patients who developed local. The other abbreviations are same as
in Fig. 1.
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dose-fractionation schedules in 81 patients with 92 lung
lesions and determined the dose–response curve using
BED. They figured out that the estimated 50% probability
of tumor control dose with BED10Gy was 49.9 Gy at the
periphery of PTV and 94.2 Gy at the IC. They also evalu-
ated the data from several published studies and concluded
that the peripheral dose to the PTV was the significant
factor determining LC.
Our negative result in correlation between LC and dose–
volume factors is attributed to several factors. First, the var-
iations in dose distribution might be too small to find any
differences affecting clinical outcome. Both Onishi et al.
[7] and Wulf et al. [11] showed the effect of dose–volume
metrics on LR rate comparing different dose-fractionation
schedules. In the Onishi study, BED10Gy ranged from 57.6
Gy to 180 Gy at IC. Similarly, in the Wulf study, BED10Gy
ranged from 93.6 Gy to 262.5 Gy at IC and from 64 Gy to
180 Gy at PTVD95. On the other hand, our study used a
uniform dose-fractionation of 48 Gy in four fractions at the
IC under BPL. Under AAA, the IC dose ranged from 43.1
Gy to 49.6 Gy, the equivalent of 89.5 Gy to 111.1 Gy in
BED10Gy, and PTV D95 ranged from 36.1 Gy to 46.3 Gy,
the equivalent of 68.7 Gy to 99.9 Gy in BED10Gy,
respectively.
Second, the calculated dose distributions have been differ-
ent from the delivered dose distributions in the patients,
even using more advanced algorithms. Although AAA is su-
perior to BPL for heterogeneity correction, it still has a cal-
culation error [14, 15]. In our previous report, most LR
occurred within 3 years and LR rate was 13.2% at both 3
and 5 years [6]. This means it takes at least 3 years to evalu-
ate the clinical outcome of LR rate appropriately. To assess
the relationship between dose–volume metrics and LR, the
patients who were treated several years ago were also
included in this study and the median follow-up duration in
our study reached 35.9 months. At that time, a more correct
calculation algorithm, the Monte Carlo simulation, was not
available in a commercial radiation treatment planning
system, and it is difficult to recalculate dose distribution in
another calculation system with Monte Carlo.
Third, there are limitations to evaluating the dose distri-
bution of lung tumors, which displace and deform intrafrac-
tionally due to the respiratory motion, and also from day to
day. The range of respiration-induced lung tumor motion is
sometimes more than 3 cm [21]. To compensate for the in-
fluence of this intrafractional tumor motion, Guckenberger
et al. tried to evaluate the dose to target volume with 4D
dose calculation and stated that the 3D dose at PTV
margins underestimated the 4D dose [22]. Then, with the
quotients between 4D doses to the clinical target volume
(CTV) D95 and 3D doses to PTV D95, they also evaluated
the relationship between CTV dose and LR rate comparing
different dose-fractionation schedules and concluded that
BED10Gy to the CTV >100 Gy resulted in excellent local
control based on 4D dose calculation [23]. In addition, the
day-to-day positional errors also affect the dose distribution.
Michalski et al. [21] also assessed the intrafractional repro-
ducibility of respiratory motion using 23 pairs of repeated
4DCT tumor motion, and showed that three cases did not
exhibit similarity of tumor motion on different days.
Galerani et al. [24] investigated the dosimetric impact of
online cone-beam CT (CBCT) guided positional correction.
They showed that without CBCT-guided positional correc-
tion the target dose reduced with respect to those of the








BPL IC dose (Gy) 48.2 [47.9–48.5] 48.2 [47.9–48.4] 0.386
PTV D95 (Gy) 45.7 [43.9–46.8] 45.5 [40.9–46.5] 0.604
PTV Min (Gy) 42.9 [37.7–45.3] 42.8 [36.2–44.7] 0.881
PTV Mean (Gy) 47.7 [46.9–48.4] 47.7 [46.9–48.2] 0.550
AAA IC dose (Gy) 48.3 [43.1–49.6] 48.6 [47.4–49.5] 0.288
PTV D95 (Gy) 42.3 [36.1–46.3] 42.5 [39.5–45.2] 0.598
PTV Min (Gy) 39.1 [30.9–43.4] 39.4 [36.4–42.4] 0.596
PTV Mean (Gy) 45.5 [38.8–49.1] 45.9 [43.2–48.5] 0.450
NC IC dose (Gy) 45.0 [41.8–48.2] 44.5 [41.7–47.9] 0.239
PTV D95 (Gy) 41.9 [38.4–44.6] 41.2 [37.9–45.4] 0.120
PTV Min (Gy) 39.5 [33.6–42.6] 38.8 [33.5–43.7] 0.221
PTV Mean (Gy) 44.5 [41.1–47.1] 44.0 [41.1–47.1] 0.214
The abbreviations are as in Tables 1 and 2.
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planning, and the means and standard deviations of the re-
duction in GTV D99 and GTV D95 were –3.2 ± 4.9% and
–2.1 ± 4.4%, respectively.
These errors may have obscured the small difference in the
dose distribution between the LC and LR groups, and led to
the negative result of this study. We might need a more adap-
tive dose evaluation system to identify the factors in the
dose–volume metrics that affect the LC rate in the future.
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